Event-free survival in patients with early HER2-positive breast cancer with a pathological complete response after HER2-targeted therapy: a pooled analysis
The standard-of-care for patients with pathological complete response (pCR) after neoadjuvant human epidermal growth factor receptor 2 (HER2)-targeted therapy plus chemotherapy is continuation of HER2-targeted therapy in the adjuvant setting. Our objective was to evaluate risk of recurrence or death...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
15 October 2022
|
| In: |
Cancers
Year: 2022, Volume: 14, Issue: 20, Pages: 1-14 |
| ISSN: | 2072-6694 |
| DOI: | 10.3390/cancers14205051 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.3390/cancers14205051 Verlag, lizenzpflichtig, Volltext: https://www.mdpi.com/2072-6694/14/20/5051 
|
| Author Notes: | Sandra M. Swain, Harrison Macharia, Javier Cortes, Chau Dang, Luca Gianni, Sara A. Hurvitz, Christian Jackisch, Andreas Schneeweiss, Dennis Slamon, Pinuccia Valagussa, Yolande du Toit, Dominik Heinzmann, Adam Knott, Chunyan Song and Patricia Cortazar |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1831434202 | ||
| 003 | DE-627 | ||
| 005 | 20230707002313.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230118s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/cancers14205051 |2 doi | |
| 035 | |a (DE-627)1831434202 | ||
| 035 | |a (DE-599)KXP1831434202 | ||
| 035 | |a (OCoLC)1389536351 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 29 |2 sdnb | ||
| 100 | 1 | |a Swain, Sandra M. |e VerfasserIn |0 (DE-588)1136982418 |0 (DE-627)893903809 |0 (DE-576)491013728 |4 aut | |
| 245 | 1 | 0 | |a Event-free survival in patients with early HER2-positive breast cancer with a pathological complete response after HER2-targeted therapy |b a pooled analysis |c Sandra M. Swain, Harrison Macharia, Javier Cortes, Chau Dang, Luca Gianni, Sara A. Hurvitz, Christian Jackisch, Andreas Schneeweiss, Dennis Slamon, Pinuccia Valagussa, Yolande du Toit, Dominik Heinzmann, Adam Knott, Chunyan Song and Patricia Cortazar |
| 264 | 1 | |c 15 October 2022 | |
| 300 | |a 14 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 18.01.2023 | ||
| 520 | |a The standard-of-care for patients with pathological complete response (pCR) after neoadjuvant human epidermal growth factor receptor 2 (HER2)-targeted therapy plus chemotherapy is continuation of HER2-targeted therapy in the adjuvant setting. Our objective was to evaluate risk of recurrence or death in these patients and determine if outcomes differed by the HER2-targeted regimen received in each setting. We analyzed patient-level data from five randomized trials evaluating trastuzumab, pertuzumab, or both as part of systemic neoadjuvant and adjuvant therapy for HER2-positive early breast cancer, and assessed event-free survival (EFS) in 1763 patients. Patients with pCR had decreased risk of an EFS event versus those with residual disease (unadjusted hazard ratio [HR] = 0.35; 95% confidence interval [CI]: 0.27-0.46). Regardless of pCR status, after adjusting for baseline factors, reduction in EFS event risk was greater in patients administered pertuzumab/trastuzumab in both settings versus those administered only trastuzumab in both settings (HR = 0.36; 95% CI: 0.26-0.49), or pertuzumab/trastuzumab in the neoadjuvant setting and only trastuzumab in the adjuvant setting (HR = 0.67; 95% CI: 0.47-0.96). Patients with pCR had longer EFS than those with residual disease. Patients treated with pertuzumab/trastuzumab in both the neoadjuvant and adjuvant settings had the lowest risk of breast cancer recurrence. | ||
| 650 | 4 | |a dual HER2 targeting | |
| 650 | 4 | |a early breast cancer | |
| 650 | 4 | |a event-free survival | |
| 650 | 4 | |a HER2 | |
| 650 | 4 | |a pathologic complete response | |
| 650 | 4 | |a pertuzumab | |
| 650 | 4 | |a trastuzumab | |
| 700 | 1 | |a Macharia, Harrison |e VerfasserIn |4 aut | |
| 700 | 1 | |a Cortes, Javier |e VerfasserIn |4 aut | |
| 700 | 1 | |a Dang, Chau |e VerfasserIn |4 aut | |
| 700 | 1 | |a Gianni, Luca |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hurvitz, Sara A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Jackisch, Christian |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schneeweiss, Andreas |d 1961- |e VerfasserIn |0 (DE-588)109972554 |0 (DE-627)632849630 |0 (DE-576)327251859 |4 aut | |
| 700 | 1 | |a Slamon, Dennis |e VerfasserIn |4 aut | |
| 700 | 1 | |a Valagussa, Pinuccia |e VerfasserIn |4 aut | |
| 700 | 1 | |a Du Toit, Yolande |e VerfasserIn |4 aut | |
| 700 | 1 | |a Heinzmann, Dominik |e VerfasserIn |4 aut | |
| 700 | 1 | |a Knott, Adam |e VerfasserIn |4 aut | |
| 700 | 1 | |a Song, Chunyan |e VerfasserIn |4 aut | |
| 700 | 1 | |a Cortazar, Patricia |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancers |d Basel : MDPI, 2009 |g 14(2022), 20, Artikel-ID 5051, Seite 1-14 |h Online-Ressource |w (DE-627)614095670 |w (DE-600)2527080-1 |w (DE-576)313958548 |x 2072-6694 |7 nnas |a Event-free survival in patients with early HER2-positive breast cancer with a pathological complete response after HER2-targeted therapy a pooled analysis |
| 773 | 1 | 8 | |g volume:14 |g year:2022 |g number:20 |g month:15 |g elocationid:5051 |g pages:1-14 |g extent:14 |a Event-free survival in patients with early HER2-positive breast cancer with a pathological complete response after HER2-targeted therapy a pooled analysis |
| 856 | 4 | 0 | |u https://doi.org/10.3390/cancers14205051 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.mdpi.com/2072-6694/14/20/5051 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20230118 | ||
| 993 | |a Article | ||
| 994 | |a 2022 | ||
| 998 | |g 109972554 |a Schneeweiss, Andreas |m 109972554:Schneeweiss, Andreas |d 910000 |d 910400 |d 50000 |e 910000PS109972554 |e 910400PS109972554 |e 50000PS109972554 |k 0/910000/ |k 1/910000/910400/ |k 0/50000/ |p 8 | ||
| 999 | |a KXP-PPN1831434202 |e 4249565068 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"physDesc":[{"extent":"14 S."}],"language":["eng"],"recId":"1831434202","id":{"eki":["1831434202"],"doi":["10.3390/cancers14205051"]},"relHost":[{"name":{"displayForm":["Molecular Diversity Preservation International (MDPI)"]},"id":{"issn":["2072-6694"],"zdb":["2527080-1"],"eki":["614095670"]},"recId":"614095670","language":["eng"],"disp":"Event-free survival in patients with early HER2-positive breast cancer with a pathological complete response after HER2-targeted therapy a pooled analysisCancers","physDesc":[{"extent":"Online-Ressource"}],"part":{"year":"2022","issue":"20","text":"14(2022), 20, Artikel-ID 5051, Seite 1-14","volume":"14","pages":"1-14","extent":"14"},"origin":[{"dateIssuedKey":"2009","dateIssuedDisp":"2009-","publisherPlace":"Basel","publisher":"MDPI"}],"type":{"bibl":"periodical","media":"Online-Ressource"},"title":[{"title_sort":"Cancers","title":"Cancers"}],"pubHistory":["1.2009 -"],"note":["Gesehen am 27.05.2020"]}],"name":{"displayForm":["Sandra M. Swain, Harrison Macharia, Javier Cortes, Chau Dang, Luca Gianni, Sara A. Hurvitz, Christian Jackisch, Andreas Schneeweiss, Dennis Slamon, Pinuccia Valagussa, Yolande du Toit, Dominik Heinzmann, Adam Knott, Chunyan Song and Patricia Cortazar"]},"note":["Gesehen am 18.01.2023"],"person":[{"display":"Swain, Sandra M.","given":"Sandra M.","family":"Swain","role":"aut"},{"given":"Harrison","family":"Macharia","display":"Macharia, Harrison","role":"aut"},{"role":"aut","family":"Cortes","given":"Javier","display":"Cortes, Javier"},{"role":"aut","display":"Dang, Chau","given":"Chau","family":"Dang"},{"given":"Luca","family":"Gianni","display":"Gianni, Luca","role":"aut"},{"role":"aut","family":"Hurvitz","given":"Sara A.","display":"Hurvitz, Sara A."},{"display":"Jackisch, Christian","family":"Jackisch","given":"Christian","role":"aut"},{"display":"Schneeweiss, Andreas","family":"Schneeweiss","given":"Andreas","role":"aut"},{"display":"Slamon, Dennis","given":"Dennis","family":"Slamon","role":"aut"},{"role":"aut","display":"Valagussa, Pinuccia","given":"Pinuccia","family":"Valagussa"},{"display":"Du Toit, Yolande","family":"Du Toit","given":"Yolande","role":"aut"},{"display":"Heinzmann, Dominik","given":"Dominik","family":"Heinzmann","role":"aut"},{"role":"aut","given":"Adam","family":"Knott","display":"Knott, Adam"},{"role":"aut","display":"Song, Chunyan","family":"Song","given":"Chunyan"},{"display":"Cortazar, Patricia","family":"Cortazar","given":"Patricia","role":"aut"}],"title":[{"title":"Event-free survival in patients with early HER2-positive breast cancer with a pathological complete response after HER2-targeted therapy","title_sort":"Event-free survival in patients with early HER2-positive breast cancer with a pathological complete response after HER2-targeted therapy","subtitle":"a pooled analysis"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"origin":[{"dateIssuedDisp":"15 October 2022","dateIssuedKey":"2022"}]} | ||
| SRT | |a SWAINSANDREVENTFREES1520 | ||